EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults

Huiling Qin, Yan Tan, Lei Diao, Ai-Min Hui, Zhuli Wu, Yongchun Zhou, Juan Sun, Xiao Xiang, Jingjun Qiu, Wei Hu

Drugs in R&D · 2023

DOI: 10.1007/s40268-023-00446-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drugs in R&D, 2023. Verfasst von Huiling Qin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. Hauptthemen laut MEDLINE: East Asian People, Protein-Tyrosine Kinases, Diet, High-Fat. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shanghai Fosun Pharmaceutical Development Co., Ltd and Wanbang Biopharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: This study was conducted to investigate the effect of high-fat meals on the pharmacokinetics (PK) and safety profile of SAF-189s, a novel ALK/ROS1 inhibitor. METHODS: This was a single-center, phase I, open-label, crossover study in which healthy adults (≥18 years) were randomized (1:1) to two sequences of SAF-189s administration (fasted-fed or fed-fasted) separated by a 14-day washout. After a ≥10-h overnight fast, volunteers received SAF-189s 160 mg orally in a fasted state or 30 min after a high-fat, high-calorie meal. Similarity of pharmacokinetic parameters was concluded if the 90% CI for the geometric mean ratio (GMR) between the fed and fasted group fell within the predefined range of 0.80-1.25. RESULTS: In total, 24 subjects were enrolled and 23 completed the study. SAF-189s maximum plasma concentration (Cmax; GMR: 109.1% [90% CI 103.1-115.4]) was comparable under fed (high-fat meal, n = 24) versus fasted (n = 23) conditions, with no effect on area under the plasma concentration-time curve from time 0 to t (AUC0-t; GMR: 105.1% [90% CI 100.3-110.2]) and AUC from time 0 to infinity (AUC0-∞; GMR: 105.5% [90% CI, 100.6-110.6]). In both groups, the median time to maximum plasma concentration (tmax) was around 6 h and mean plasma half-life (t½) was around 35 h. Fed administration led to a lower incidence of treatment-emergent adverse events (TEAEs; 29.2% vs 54.2%), including gastrointestinal disorders (4.2% vs 41.7%) and headache (0.0% vs 12.5%), versus fasted administration. CONCLUSIONS: A high-fat meal had minimal effect on the pharmacokinetic profile of SAF-189s compared with a fasted state following a single dose of 160 mg. Administration with a high-fat meal led to a lower incidence of TEAEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

East Asian PeopleProtein-Tyrosine KinasesDiet, High-FatAdultHumansAdministration, OralArea Under CurveBiological AvailabilityCross-Over StudiesFastingFood-Drug InteractionsHealthy VolunteersProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases

Substanzen

Protein-Tyrosine KinasesProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesROS1 protein, human

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
  • Shanghai Fosun Pharmaceutical Development Co., Ltd., 1289 Yishan Road, Shanghai, 200233, China.
  • EnCureGen Pharma, 9 Yayingshi Road, Huangpu District, Guangzhou, 510700, China.
  • Wanbang Biopharmaceuticals, 6 Yangshan Road, Economic Zone, Xuzhou, 221004, Jiangsu, China.
  • Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. huwei@ahmu.edu.cn.

Förderung

  • Shanghai Fosun Pharmaceutical Development Co., Ltd and Wanbang Biopharmaceuticals

Zitieren

APA

Qin, H., Tan, Y., Diao, L., Hui, A. M., Wu, Z., Zhou, Y., Sun, J., Xiang, X., Qiu, J., & Hu, W. (2023). Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults. Drugs in R&D. https://doi.org/10.1007/s40268-023-00446-2

Vancouver

Qin H, Tan Y, Diao L, Hui AM, Wu Z, Zhou Y, et al. Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults. Drugs in R&D. 2023. doi:10.1007/s40268-023-00446-2

BibTeX
@article{Qin2023,
  author = {Qin, Huiling and Tan, Yan and Diao, Lei and Hui, Ai-Min and Wu, Zhuli and Zhou, Yongchun and Sun, Juan and Xiang, Xiao and Qiu, Jingjun and Hu, Wei},
  title = {Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults},
  journal = {Drugs in R&D},
  year = {2023},
  doi = {10.1007/s40268-023-00446-2}
}
Kostenlos starten →